A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Fan, Xuejun ^a   Brezski, Randall J ^b   Fa, Ming ^a   Deng, Hui ^a   Oberholtzer, Allison ^b   Gonzalez, Anneliese ^a   Dubinsky, William P ^c   Strohl, William R ^b   Jordan, Robert E ^b   Zhang, Ningyan ^a   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GELATINASE A; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEINASE; STROMELYSIN; TRASTUZUMAB; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR XENOGRAFT; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NEOPLASMS; PATHOLOGY; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN BINDING; PROTEOLYSIS; RECEPTOR, ERBB-2; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864535959     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3240     Document Type: Article

References (49)

1. Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc) 1999, 35:931-946.
2. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507, 19884552.
3. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446. 10.1038/74704, 10742152.
4. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
5. Wilken JA, Maihle NJ. Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci 2010, 1210:53-65. 10.1111/j.1749-6632.2010.05782.x, 3045786, 20973799.
6. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21:255-262. 10.1093/annonc/mdp304, 19633047.
7. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O''Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9:1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
8. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in 'resistant' breast carcinoma cells. Cancer Res 2009, 69:2191-2194. 10.1158/0008-5472.CAN-08-1056, 19276389.
9. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004, 108:334-341. 10.1002/ijc.11445, 14648698.
10. Shattuck DL, Miller JK, Carraway KL, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008, 68:1471-1477. 10.1158/0008-5472.CAN-07-5962, 18316611.
11. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010, 70:299-308. 10.1158/0008-5472.CAN-09-1845, 20028874.
12. Porter RR. Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature 1958, 182:670-671. 10.1038/182670a0, 13590068.
13. Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science 1960, 132:1770-1771. 10.1126/science.132.3441.1770, 13729245.
14. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002, 21:1607-1615. 10.1093/emboj/21.7.1607, 125946, 11927545.
15. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008, 45:1837-1846. 10.1016/j.molimm.2007.10.043, 18157932.
16. Mehta SK, Plaut AG, Calvanico NJ, Tomasi TB. Human immunoglobulin A: production of an Fc fragment by an enteric microbial proteolytic enzyme. J Immunol 1973, 111:1274-1276.
17. Senior BW, Woof JM. Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases. Infect Immun 2005, 73:1515-1522. 10.1128/IAI.73.3.1515-1522.2005, 1064975, 15731049.
18. Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, Luongo JL, Oberholtzer A, Knight DM, Jordan RE. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci USA 2009, 106:17864-17869. 10.1073/pnas.0904174106, 2758810, 19815504.
19. Brezski RJ, Knight DM, Jordan RE. The origins, specificity, and potential biological relevance of human anti-IgG hinge autoantibodies. ScientificWorldJournal 2011, 11:1153-1167.
20. Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, Schmidt AP, Kruszynski M, Whitaker BP, Knight DM, Jordan RE. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008, 181:3183-3192.
21. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?. MAbs 2010, 2:212-220. 10.4161/mabs.2.3.11780, 2881249, 20400859.
22. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999, 27:1533-1541. 10.1016/S0301-472X(99)00089-2, 10517495.
23. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005, 11:4898-4904. 10.1158/1078-0432.CCR-04-2476, 16000588.
24. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655. 10.1158/1078-0432.CCR-04-0225, 15355889.
25. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006, 94:259-267. 10.1038/sj.bjc.6602930, 2361112, 16404427.
26. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A, Fagnoni FF. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-11999. 10.1158/0008-5472.CAN-07-2068, 18089830.
27. Goetz H, Kuschel M, Wulff T, Sauber C, Miller C, Fisher S, Woodward C. Comparison of selected analytical techniques for protein sizing, quantitation and molecular weight determination. J Biochem Biophys Methods 2004, 60:281-293. 10.1016/j.jbbm.2004.01.007, 15345296.
28. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740. 10.1074/jbc.M202069200, 11986321.
29. Zhang N, Liu L, Dan Dumitru C, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, Ou Y, Patel RN, Vo K, Wang H, Burnina I, Choi BK, Huber HE, Stadheim TA, Zha D. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 2011, 3:289-298. 10.4161/mabs.3.3.15532, 3149709, 21487242.
30. Hellman U, Wernstedt C, Gonez J, Heldin CH. Improvement of an 'In-Gel' digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal Biochem 1995, 224:451-455. 10.1006/abio.1995.1070, 7710111.
31. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:201-212. 10.1007/s10911-010-9177-x, 2886087, 20440544.
32. Vincents B, von Pawel-Rammingen U, Bjorck L, Abrahamson M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 2004, 43:15540-15549. 10.1021/bi048284d, 15581366.
33. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem 2010, 285:35944-35956. 10.1074/jbc.M109.091769, 2975217, 20837483.
34. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
35. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2010, 278:16-27.
36. Mukherjee S, Roth MJ, Dawsey SM, Yan W, Rodriguez-Canales J, Erickson HS, Hu N, Goldstein AM, Taylor PR, Richardson AM, Tangrea MA, Chuaqui RF, Emmert-Buck MR. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med 2010, 8:91. 10.1186/1479-5876-8-91, 2958908, 20920372.
37. Delassus GS, Cho H, Eliceiri GL. New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol 2011, 226:3378-3384. 10.1002/jcp.22694, 21344390.
38. Saridaki Z, Georgoulias V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 2010, 16:1177-1187. 10.3748/wjg.v16.i10.1177, 2839169, 20222160.
39. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
40. Johansson BP, O S, Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One 2008, 3:e1692. 10.1371/journal.pone.0001692, 2253494, 18301769.
41. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7:2517-2527. 10.1158/1535-7163.MCT-08-0201, 18723496.
42. Abdullah N, Greenman J, Pimenidou A, Topping KP, Monson JR. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol Immunother 1999, 48:517-524. 10.1007/s002620050600, 10602889.
43. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008, 6:25. 10.1186/1479-5876-6-25, 2415031, 18485193.
44. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184:512-520. 10.4049/jimmunol.0900847, 19949082.
45. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3:e3065. 10.1371/journal.pone.0003065, 2516933, 18725974.
46. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61:4892-4900.
47. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012, 18:3478-3486. 10.1158/1078-0432.CCR-11-2294, 22504044.
48. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51. 10.1016/j.cell.2010.03.014, 20371344.
49. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. 10.1038/nrc2618, 3251309, 19279573.